- Introduction
Stephen RD Johnston; Charles Swanton - The prognostic and predictive value of gene expression signatures in breast cancer
Hatem A. Azim, Jr., Debora Fumagalli, Christos Sotiriou - Targeting ER positive metastatic breast cancer
Stephen RD Johnston - Targeting HER2+ and Trastuzumab Resistant metastatic breast cancer
Javier Cortes - Targeting Triple Negative Sporadic and hereditary BRCA related metastatic Breast Cancer
Sarah Barton; Nick Turner - Chemotherapy and metastatic breast cancer
Charles Swanton - Bisphosphonates and their role in metastatic breast cancer
David A Cameron - Targeting Angiogenesis in Metastatic Breast Cancer
David Miles - Imaging in the management of metastatic breast cancer
David MacVicar - Positron emission tomography/computed tomography in metastatic breast cancer
Bhupinder Sharma; Asim Afaq - Novel biomarker approaches for improving therapeutic strategies in metastatic breast cancer
Roberta Ferraldeschi; Gerhardt Attard - Palliative radiotherapy in the management of metastatic breast cancer
Anthony Chalmers; Richard Simcock - Management of neurological complications in metastatic breast cancer
Adrian Casey; Syed MR Kabir - Thoracic complications
George Ladas - Orthopaedic complications
Kuldeep K Stohr; Stuart C Evans - Thermal ablation of hepatic metastases
Andy Adam - Palliative Care and Metastatic Breast Cancer
Jayne Wood; Anna-Marie Stevens - Specialist Support Services and Information Needs for Patients
Melissa Warren; Diane Mackie
Section I – Systemic Treatments
Section II – Imaging and Response Assessment
Section III – Local Treatment Options
- Charles Swanton, PhD, MRCP, is Group leader at Translational Therapeutics Laboratory, Cancer Research-UK London Research Institute, since March 2004. He is also a medical oncologist at the Royal Marsden, UK, since July 2003. His research goals include using functional genomic approaches to investigate common regulators of cytotoxic cancer cell drug resistance and how distinct patterns of genomic instability can be optimally targeted in order to develop new strategies to limit the acquisition of multi-drug resistance in vivo.
- Stephen Johnston, MA, PhD, FRCP, is Consultant Medical Oncologist and Director of Clinical R&D at the Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London. He graduated in 1983 from Trinity College at The University of Cambridge, and in 1986 from The Medical School at The University of Newcastle upon Tyne. He trained in General Medicine at St Bartholomew's Hospital and Hammersmith Hospital in London, and subsequently in Medical Oncology at the Royal Marsden Hospital. He gained his PhD from the Institute of Cancer Research at the University of London, and took up his current position as Medical Oncologist on the Breast Unit at the Royal Marsden Hospital in 1997.
Dr Johnston has a specialist interest in the treatment of metastatic breast cancer, and his major research interests lie in understanding mechanisms of endocrine resistance in breast cancer. He is actively involved in facilitating the interface between basic and applied research, and is chief investigator of several phase II / III trials of novel therapeutic approaches in advanced disease, including new endocrine therapies and targeted signal transduction inhibitors. He has published over 150 breast cancer related articles in peer-reviewed journals. He is a member of several national and international committees, and is Deputy Editor of the international journal Breast Cancer Research and a Trustee of the UK charity ‘Breast Cancer Campaign’.
